OmniAb (OABI) Income from Continuing Operations (2021 - 2026)
OmniAb (OABI) posted quarterly Income from Continuing Operations of 7707000.0 for Q1 2026, up 57.65% year-over-year from 4888558.18 in Q1 2025, and up 45.64% quarter-over-quarter from 14179000.0 in Q4 2025.
OmniAb (OABI) Income from Continuing Operations (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Income from Continuing Operations for 6 consecutive years, with 7707000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 57.65% year-over-year to 7707000.0; the TTM figure through Mar 2026 stood at 54286000.0 (up 11.4% YoY), while the FY2025 annual figure was 64779000.0, down 4.43% from the prior year.
- Income from Continuing Operations improved to 7707000.0 in Q1 2026 per OABI's latest filing, from 14179000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 6820000.0 in Q4 2022 and bottomed at 18961000.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 12204235.29 across 5 years, with a median of 14053000.0 in 2023.
- On a YoY basis, Income from Continuing Operations climbed as much as 118.97% in 2022 and fell as far as 470197.48% in 2022.
- OmniAb's Income from Continuing Operations stood at 6820000.0 in 2022, then sank by 306.06% to 14053000.0 in 2023, then gained by 7.01% to 13068000.0 in 2024, then slipped by 8.5% to 14179000.0 in 2025, then soared by 45.64% to 7707000.0 in 2026.
- Business Quant data shows OABI's Income from Continuing Operations at 7707000.0 in Q1 2026, 14179000.0 in Q4 2025, and 16525000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | -5.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.86 Mn |
| Mar 31, 2026 | -7.71 Mn |
| Dec 31, 2025 | -14.18 Mn |
| Sep 30, 2025 | -16.53 Mn |
| Jun 30, 2025 | -15.88 Mn |
| Mar 31, 2025 | -18.20 Mn |
| Dec 31, 2024 | -13.07 Mn |
| Sep 30, 2024 | -16.37 Mn |
| Jun 30, 2024 | -13.63 Mn |
| Mar 31, 2024 | -18.96 Mn |
| Dec 31, 2023 | -14.05 Mn |
| Sep 30, 2023 | -15.74 Mn |
| Jun 30, 2023 | -14.73 Mn |
| Mar 31, 2023 | -6.10 Mn |
| Dec 31, 2022 | 6.82 Mn |
| Sep 30, 2022 | -12.60 Mn |
| Jun 30, 2022 | -10.28 Mn |
| Mar 31, 2022 | -6.28 Mn |
| Dec 31, 2021 | -35.95 Mn |
| Sep 30, 2021 | -170,579.00 |